Humanistic burden in schizophrenia: A literature review

Journal of Psychiatric Research

Volumn 54, Issue 1, 2014, Pages 85-93

  Millier, A ^a   Schmidt, U ^b   Angermeyer, M C ^c,d   Chauhan, D ^e   Murthy, V ^e   Toumi, M ^f   Cadi Soussi, N ^g  

^a CREATIV CEUTICAL   (France)

^b Luxembourg ^*  (Luxembourg)

^c Center for Public Mental Health   (Austria)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e Takeda Pharmaceutical Company   (United Kingdom)

^f UNIVERSITÉ LYON 1   (France)

^g Takeda Pharmaceuticals International GmbH   (Switzerland)

Author keywords

Antipsychotics; Disease burden; Humanistic burden; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

CAREGIVER BURDEN; COGNITIVE DEFECT; DEPRESSION; HOMELESSNESS; HUMAN; METABOLIC DISORDER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUICIDE; VIOLENCE; CAREGIVER; COGNITION DISORDERS; COMPLICATION; COST OF ILLNESS; ECONOMICS; FACTUAL DATABASE; FAMILY; PSYCHOLOGY; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; CAREGIVERS; COGNITION DISORDERS; COST OF ILLNESS; DATABASES, FACTUAL; DEPRESSION; FAMILY; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84899897335     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.03.021     Document Type: Review

References (82)

1. Abouzaid S., Jutkowitz E., Foley K.A., Pizzi L.T., Kim E., Bates J. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag 2010 Oct, 13(5):247-254.
2. Allardyce J., van Os J. Long-term course and outcome of schizophrenia. PreviousPsychiatry 2008 Oct, 7(10):440-442.
3. Alvarez-Jiménez M., González-Blanch C., Vázquez-Barquero J.L., Pérez-Iglesias R., Martínez-García O., Pérez-Pardal T., et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006, 67(8):1253-1260.
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 Mar, 162(3):441-449.
5. Angermeyer M.C., Dietrich S. Public beliefs about and attitudes toward people with mental illness: a review of population studies. Acta Psychiatr Scand 2006, 113:163-179.
6. Auquier P., Tinland A., Fortanier C., Loundou A., Baumstarck K., Lancon C., et al. Toward meeting the needs of homeless people with schizophrenia: the validity of quality of life measurement. PLoS One 2013 Oct 25, 8(10):e79677.
7. Awad A.G., Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004, 18(13):877-893.
8. Awad A.G., Voruganti L.N. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics 2012 Mar, 30(3):183-195.
9. Backer T.E., Howard E.A. Cognitive impairments and the prevention of homelessness: research and practice review. J Prim Prev 2007 Jul, 28(3-4):375-388.
10. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008 Apr, 23(3):201-209.
11. Baumstarck K., Boyer L., Boucekine M., Aghababian V., Parola N., Lançon C., et al. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr Res 2013 Jun, 147(1):58-67.
12. Bo S., Abu-Akel A., Kongerslev M., Haahr U.H., Simonsen E. Risk factors for violence among patients with schizophrenia. Clin Psychol Rev 2011 Jul, 31(5):711-726.
13. Bobes J., Garcia-Portilla M.P., Bascaran M.T., Saiz P.A., Bousoño M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci 2007, 9(2):215-226. Review.
14. Boyer L., Millier A., Perthame E., Aballea S., Auquier P., Toumi M. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry 2013 Jan 9, 13:15.
15. Braga R.J., Mendlowicz M.V., Marrocos R.P., Figueira I.L. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005 Jul, 39(4):409-414.
16. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997, 171:502-508.
17. Brown S., Barraclough B., Inskip H. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000 Sep, 177:212-217.
18. Burda K., Czubak A., Nowakowska E., Kus K., Metelska J., Nowakowska A. Interactions of nicotine and drugs used in the treatment of mental illnesses with respect to cognitive functions. Arzneimittelforschung 2010, 60(9):527-543.
19. Bushe C.J., Taylor M., Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010 Nov, 24(4 Suppl.):17-25.
20. Caqueo-Urízar A., Gutiérrez-Maldonado J., Miranda-Castillo C. Quality of life in caregivers of patients with schizophrenia: a literature review. Health Qual Life Outcomes 2009 Sep 11, 7:84.
21. Carlborg A., Winnerbäck K., Jönsson E.G., Jokinen J., Nordström P. Suicide in schizophrenia. Expert Rev Neurother 2010 Jul, 10(7):1153-1164.
22. Chuang H.T., Atkinson M. AIDS knowledge and high-risk behavior in the chronic mentally ill. Can J Psychiatry 1996, 41:269-272.
23. Citrome L., Vreeland L. Obesity and mental illness. Mod Trends Pharmacopsychiatry 2009, 26:25-46.
24. Clark S.L., Adkins D.E., van den Oord E.J. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res 2011 Nov, 132(2-3):114-120.
25. Conley R.R., Ascher-Svanum H., Zhu B., Faries D.E., Kinon B.J. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007 Feb, 90(1-3):186-197.
26. Cook J.A., Razzano L. Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice. Schizophr Bull 2000, 26(1):87-103.
27. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar, 161(3):414-425.
28. Corrigan P.W., Markowitz F.E., Watson A.C. Structural levels of mental illness stigma and discrimination. Schizophr Bull 2004, 30(3):481-491.
29. Culhane M.A., Schoenfeld D.A., Barr R.S., Cather C., Deckersbach T., Freudenreich O., et al. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry 2008 Nov, 69(11):1743-1750.
30. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009 Sep, 24(6):412-424.
31. de Silva J., Hanwella R., de Silva V.A. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. Ceylon Med J 2012 Mar, 57(1):14-18.
32. Desai M.M., Rosenheck R.A., Druss B.G., Perlin J.B. Mental disorders and quality of diabetes care in the Veterans health administrations. Am J Psychiatry 2002 Sep, 159(9):1584-1590.
33. Druss B.G., Bradford W.D., Rosenheck R.A., Radford M.J., Krumholz H.M. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000 Jan 26, 283(4):506-511.
34. Folsom D., Jeste D.V. Schizophrenia in homeless persons: a systematic review of the literature. Acta Psychiatr Scand 2002 Jun, 105(6):404-413.
35. Hannerz H., Borgâ P., Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public Health 2001 Sep, 115(5):328-337.
36. Hawton K., Sutton L., Haw C., Sinclair J., Deeks J.J. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005 Jul, 187:9-20. Review.
37. Hjorthøj C., Fohlmann A., Nordentoft M. Reprint of "Treatment of cannabis use disorders in people with schizophrenia spectrum disorders-a systematic review". Addict Behav 2009 Oct, 34(10):846-851.
38. Hodgins S. Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention. Philos Trans R Soc Lond B Biol Sci 2008 Aug 12, 363(1503):2505-2518.
39. Hor K., Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010 Nov, 24(4 Suppl.):81-90.
40. Ismail K. Physical health in schizophrenia and related disorders. Psychiatry 2008 Nov, 7(11):472-476.
41. Jones R.M., Lichtenstein P., Grann M., Långström N., Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. J Clin Psychiatry 2011 Jun, 72(6):775-779.
42. Jungbauer J., Stelling K., Dietrich S., Angermeyer M.C. Schizophrenia: problems of separation in families. J Adv Nurs 2004 Sep, 47(6):605-613.
43. Katschnig H. Schizophrenia and quality of life. Acta Psychiatr Scand Suppl 2000, 407:33-37.
44. Kelly B.D. Structural violence and schizophrenia. Soc Sci Med 2005 Aug, 61(3):721-730.
45. Koponen H., Alaräisänen A., Saari K., Pelkonen O., Huikuri H., Raatikainen M.J., et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 2008, 62(5):342-345.
46. Koskinen J., Löhönen J., Koponen H., Isohanni M., Miettunen Prevalence of alcohol use disorders in schizophrenia-a systematic review and meta-analysis. Acta Psychiatr Scand 2009 Aug, 120(2):85-96.
47. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007 Nov, 116(5):317-333.
48. Levinson M.C., Druss B.G., Dombrowski E.A., Rosenheck R.A. Barriers to primary medical care among patients in a community mental health center. Psychiatr Serv 2003 Aug, 54(8):1158-1160.
49. Link B.G., Phelan J.C. Conceptualizing stigma. Annu Rev Sociol 2001, 27:363-385.
50. Lögdberg B., Nilsson L.L., Levander M.T., Levander S. Schizophrenia, neighbourhood, and crime. Acta Psychiatr Scand 2004 Aug, 110(2):92-97.
51. McDonell M.G., Short R.A., Berry C.M., Dyck D.G. Burden in schizophrenia caregivers: impact of family psychoeducation and awareness of patient suicidality. Fam Process 2003 Spring, 42(1):91-103.
52. Montejo A.L., Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008, 34(3):227-239.
53. Mulholland C., Cooper S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat 2000, 6:169-177.
54. Nanko S., Moridaira J. Reproductive rates in schizophrenic outpatients. Acta Psychiatr Scand 1993 Jun, 87(6):400-404.
55. Palmer B.A., Pankratz V.S., Bostwick J.M. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005 Mar, 62(3):247-253.
56. Pinikahana J., Happell B., Hope J., Keks N.A. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs 2002 Jun, 11(2):103-111.
57. Pompili M., Amador X.F., Girardi P., Harkavy-Friedman J., Harrow M., Kaplan K., et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007 Mar 16, 6:10.
58. Rafiyah I. Review: burden on family caregivers caring for patients with schizophrenia and its related factors. Nurse Media J Nurs 2011, 1(1):29-41.
59. Romans S. Sexuality in women with schizophrenia. Curr Women's Health Rev 2010 Feb, 6(1):3-11.
60. Rüsch N., Angermeyer M.C., Corrigan P.W. Mental illness stigma: concepts, consequences, and initiatives to reduce stigma. Eur Psychiatry 2005 Dec, 20(8):529-539.
61. Salkow K., Fichter M. Homelessness and mental illness. Curr Opin Psychiatry 2003 Jul, 16(4):467-471.
62. Schennach-Wolff R., Obermeier M., Seemüller F., Jäger M., Messer T., Laux G., et al. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand 2011 Mar, 123(3):228-238.
63. Schmitz N., Kruse J., Kugler J. The association between physical exercises and health-related quality of life in subjects with mental disorders: results from a cross-sectional survey. Prev Med 2004 Dec, 39(6):1200-1207.
64. Schomerus G., Schwahn C., Holzinger A., Corrigan P.W., Grab H.J., Carta M.G., et al. Evolution of public beliefs about mental disorders and attitudes towards the mentally ill. A systematic review and meta-analysis. Acta Psychiatr Scand 2012 Jun, 125(6):440-452.
65. Schulze B., Angermeyer M.C. Subjective experience of stigma: a focus group study of schizophrenic patients, their relatives and mental health professionals. Soc Sci Med 2003, 56:299-312.
66. Seeman M.V. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull 2009 Sep, 35(5):937-948. Epub 2008 Apr 9.
67. Sevy S., Nathanson K., Schechter C., Fulop G. Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia. Schizophr Bull 2001, 27(4):643-651.
68. Shrivastava A., Johnston M.E., Thakar M., Shrivastava S., Sarkhel G., Sunita I., et al. Origin and impact of stigma and discrimination in schizophrenia - patients' perception: Mumbai study. Stigma Res Action 2011, 1(1):67-72.
69. Siris S.G. Suicide and schizophrenia. J Psychopharmacol 2001, 15(2):127-135.
70. Swartz M.S., Wagner H.R., Swanson J.W., Stroup T.S., McEvoy J.P., Canive J.M., et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006 Mar, 194(3):164-172.
71. Tiihonen J., Isohanni M., Räsänen P., Koiranen M., Moring J. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort. Am J Psychiatry 1997 Jun, 154(6):840-845.
72. Van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006 Feb, 113(2):91-95.
73. Vancampfort D., Sweers K., Probst M., Maurissen K., Knapen J., Minguet P., et al. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia. Diabetes Metab 2011 Sep, 37(4):318-323.
74. Viertiö S., Tuulio-Henriksson A., Perälä J., Saarni S.I., Koskinen S., Sihvonen M., et al. Activities of daily living, social functioning and their determinants in persons with psychotic disorder. Eur Psychiatry 2012 Aug, 27(6):409-415.
75. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000 Jun 16, 43(2-3):135-145.
76. Walsh E., Buchanan A., Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry 2002 Jun, 180:490-495. Review.
77. Ward A., Ishak K., Proskorovsky I., Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006 Nov, 28(11):1912-1921.
78. Webb R., Abel K., Pickles A., Appleby L. Mortality in offspring of parents with psychotic disorders: a critical review and meta-analysis. Am J Psychiatry 2005 Jun, 162(6):1045-1056.
79. Willis M., Svensson M., Löthgren M., Eriksson B., Berntsson A., Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010 Dec, 11(6):585-594.
80. Winterer G. Why do patients with schizophrenia smoke?. Curr Opin Psychiatry 2010 Mar, 23(2):112-119.
81. Wobrock T., Soyka M. Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opin Pharmacother 2009 Feb, 10(3):353-367.
82. Wright P.A., Kloos B. Housing environment and mental health outcomes: a levels of analysis perspective. J Environ Psychol 2007 Mar, 27(1):79-89.